Genmab's Epcoritamab Data Signals a Paradigm Shift in Lymphoma Care

COPENHAGEN, Denmark – June 29, 2026 – In a significant development for oncology, Genmab and partner AbbVie have announced compelling topline results from a Phase 3 trial that could fundamentally alter the treatment landscape for a common and aggressive blood cancer. The data from the EPCORE® DLBCL-4 study shows that their subcutaneously administered bispecific antibody, epcoritamab, when combined with lenalidomide, delivered a statistically significant and clinically meaningful improvement in outcomes for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

According to the announcement, the chemotherapy-free combination reduced the risk of disease progression or death by a remarkable 60% compared to the standard-of-care chemotherapy regimen. For a patient population often facing a grim prognosis after initial treatments fail, this result is more than just a data point; it represents a new horizon of tangible hope and a potential shift away from grueling chemotherapy protocols.

A New Standard for a Challenging Disease

Diffuse large B-cell lymphoma is the most prevalent type of non-Hodgkin lymphoma globally. While the frontline combination of rituximab and chemotherapy (R-CHOP) is curative for a majority of patients, a substantial 30-40% either do not respond or relapse after treatment. For these individuals, the path forward becomes fraught with uncertainty and increasingly toxic treatment options.

The current standard for eligible R/R DLBCL patients often involves intensive salvage chemotherapy followed by a high-dose chemotherapy and autologous stem cell transplant (ASCT). However, many patients are ineligible for this arduous process due to age, comorbidities, or their cancer being resistant to the salvage chemotherapy. For this large group, and for those who relapse after transplant, effective, well-tolerated options have been limited.

The Genmab and AbbVie trial directly addresses this significant unmet need. By evaluating epcoritamab in patients who have received at least one prior line of therapy, the study positions this novel combination as a powerful, earlier alternative. The regimen’s two most compelling features—its chemotherapy-free nature and its fixed duration of treatment—represent a profound improvement in the potential quality of life for patients. Moving away from the cumulative toxicity of traditional chemotherapy can reduce debilitating side effects, while a defined treatment endpoint frees patients from the burden of indefinite therapy.

“For years, we’ve been cycling through different combinations of cytotoxic agents for these patients, often with diminishing returns and increasing toxicity,” commented one clinical oncologist not involved in the study. “A highly effective, fixed-duration, chemo-free regimen that can be administered in an outpatient setting isn't just an incremental improvement; it’s the paradigm shift we’ve been working toward.”

Deconstructing the Data: A Bispecific Breakthrough

The engine behind this success is epcoritamab, a product of Genmab's proprietary DuoBody® technology. It is a bispecific antibody, an elegant piece of bioengineering designed to perform two functions simultaneously. One arm of the antibody binds to the CD20 protein on the surface of cancerous B-cells, while the other arm grabs onto the CD3 protein on the patient’s own T-cells—the primary soldiers of the immune system. By acting as a bridge, epcoritamab brings the killer T-cell into direct contact with the cancer cell, inducing a targeted and potent immune attack.

The trial paired this advanced immunotherapy with lenalidomide, an oral immunomodulatory drug with established efficacy in B-cell malignancies. The combination appears to be powerfully synergistic. The headline result—a hazard ratio of 0.40, signifying a 60% reduction in the risk of progression or death—is a figure that commands attention in any oncology trial, but especially in this difficult-to-treat setting. The safety profile was also reported to be consistent with the known profiles of each individual drug, suggesting the combination does not introduce unexpected or unmanageable toxicity—a critical factor for regulatory approval and clinical adoption.

“These topline results add to the growing evidence supporting the versatility of epcoritamab-based combinations, including fixed-duration epcoritamab, across lines of therapy for patients with relapsed or refractory large B-cell lymphoma who received at least one prior treatment,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab, in the company’s announcement. “With each new combination and treatment setting, we are building on our vision for epcoritamab as a core therapy across B-cell malignancies.”

Navigating a Crowded and Competitive Field

Epcoritamab does not enter the market in a vacuum. The treatment landscape for R/R DLBCL has been revolutionized in recent years by the arrival of CAR T-cell therapies and other novel agents. However, epcoritamab’s unique profile gives it several strategic advantages.

CAR T-cell therapies, while potentially curative for a subset of patients, are logistically complex, expensive, and require treatment at specialized centers. The process involves harvesting a patient’s T-cells, shipping them for genetic engineering, and waiting weeks for the final product, all while managing the risk of severe toxicities like cytokine release syndrome (CRS) and neurotoxicity. In contrast, epcoritamab is an “off-the-shelf” product. Its subcutaneous administration further distinguishes it from competitors, offering a level of convenience that intravenous CAR-T therapies and even other IV-administered bispecific antibodies, like Roche's glofitamab, cannot match. This ease of use could make it a preferred option for community oncology centers and for older or frailer patients who may not be candidates for more intensive treatments.

By demonstrating profound efficacy after just one prior line of therapy, the Genmab/AbbVie combination could carve out a significant space in the second-line setting, potentially competing with or providing an alternative to both ASCT and CAR-T for a broad swath of patients. The full data, which will be presented at an upcoming medical meeting, will be scrutinized for details on response durability and overall survival, but these topline results already position epcoritamab as a formidable player.

The Business of Breakthroughs

For Genmab and its global partner AbbVie, the success of the EPCORE DLBCL-4 trial is a major strategic victory. It validates Genmab’s antibody engineering platform and further solidifies epcoritamab’s potential as a multi-billion-dollar blockbuster franchise. For AbbVie, it adds a powerful and differentiated asset to its formidable oncology portfolio, helping to secure its leadership in hematology.

Analysts have already projected peak sales for epcoritamab in the billions, based on its initial approval in a later-line setting. These new data, supporting use in a much larger patient population at an earlier stage of disease, will almost certainly lead to upward revisions of those forecasts. The companies have stated their intent to engage with global regulatory authorities, and a swift path to expanded approval seems likely given the strength of the data and the high unmet need.

This announcement is a testament to a broader industry trend: the move toward smarter, targeted, and less burdensome cancer therapies. By successfully combining a sophisticated immunotherapy with a convenient delivery method and a patient-friendly treatment schedule, Genmab and AbbVie have not only advanced the science but also provided a clear blueprint for the future of oncology drug development, where operational execution and human-centered design are just as critical as the underlying molecular innovation.